Tokyo Tape
Sign in
← Sapporo Clinical Laboratory

Quarterly report · Q1

9776.TEDINET S100OYM4
Period2022-04-01 → 2022-06-30
Filed2022-08-10
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
MetricValuePeriodScopeSource row
Revenue¥4.9bn2022-04-01 → 2022-06-30Cons.Net sales
Revenue¥19.1bn2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥4.6bn2021-04-01 → 2021-06-30Cons.Net sales
Operating income¥132m2022-04-01 → 2022-06-30Cons.Operating income
Operating income¥292m2021-04-01 → 2021-06-30Cons.Operating income
Ordinary income¥223m2022-04-01 → 2022-06-30Cons.Ordinary income
Ordinary income¥1.6bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥294m2021-04-01 → 2021-06-30Cons.Ordinary income
Profit before tax¥222m2022-04-01 → 2022-06-30Cons.Income before income taxes
Profit before tax¥191m2021-04-01 → 2021-06-30Cons.Income before income taxes
Net income (owners)¥78m2022-04-01 → 2022-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥1.0bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥107m2021-04-01 → 2021-06-30Cons.Profit loss attributable to owners of parent
Net income¥125m2022-04-01 → 2022-06-30Cons.Profit loss
Net income¥106m2021-04-01 → 2021-06-30Cons.Profit loss
Total assets¥16.2bnat 2022-06-30Cons.Assets
Total assets¥16.1bnat 2022-03-31Cons.Assets
Total assets¥14.7bnat 2021-06-30Cons.Total assets (5-year summary)
Total liabilities¥5.8bnat 2022-06-30Cons.Liabilities
Total liabilities¥5.8bnat 2022-03-31Cons.Liabilities
Net assets / equity¥10.4bnat 2022-06-30Cons.Net assets
Net assets / equity¥10.3bnat 2022-03-31Cons.Net assets
Net assets / equity¥9.5bnat 2021-06-30Cons.Net assets (5-year summary)
Cash and deposits¥3.6bnat 2022-06-30Cons.Cash and deposits
Cash and deposits¥3.0bnat 2022-03-31Cons.Cash and deposits
EPS (basic)¥23.352022-04-01 → 2022-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥306.162021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥31.312021-04-01 → 2021-06-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio62.3%at 2022-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio62.6%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio63.0%at 2021-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 44
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-04-01 → 2022-06-30¥23m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-04-01 → 2022-06-30¥22m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-04-01 → 2022-06-30¥846,000
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-04-01 → 2022-06-30¥15m
jpcrp040300-q1r_E04950-000Clinical Testing Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥2.1bn
jpcrp040300-q1r_E04950-000Clinical Testing Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥2.1bn
jpcrp040300-q1r_E04950-000Clinical Testing Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥200m
jpcrp040300-q1r_E04950-000Dispensing Pharmacy Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥2.5bn
jpcrp040300-q1r_E04950-000Dispensing Pharmacy Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥2.5bn
jpcrp040300-q1r_E04950-000Dispensing Pharmacy Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥78m
jpcrp040300-q1r_E04950-000Medical Devices Sales And Maintenance Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥376m
jpcrp040300-q1r_E04950-000Medical Devices Sales And Maintenance Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥233m
jpcrp040300-q1r_E04950-000Medical Devices Sales And Maintenance Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥143m
jpcrp040300-q1r_E04950-000Medical Devices Sales And Maintenance Businessreportable segmentsegment profit2022-04-01 → 2022-06-30−¥3m
—segment totalrevenue2022-04-01 → 2022-06-30¥5.0bn
—segment totalrevenue external2022-04-01 → 2022-06-30¥4.9bn
—segment totalrevenue intersegment2022-04-01 → 2022-06-30¥143m
—segment totalsegment profit2022-04-01 → 2022-06-30¥275m
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-06-30¥5.0bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-06-30¥4.9bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-06-30¥144m
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-06-30¥290m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2021-04-01 → 2021-06-30¥19m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2021-04-01 → 2021-06-30¥19m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2021-04-01 → 2021-06-30¥351,000
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2021-04-01 → 2021-06-30¥11m
jpcrp040300-q1r_E04950-000Clinical Testing Businessreportable segmentrevenue2021-04-01 → 2021-06-30¥1.9bn
jpcrp040300-q1r_E04950-000Clinical Testing Businessreportable segmentrevenue external2021-04-01 → 2021-06-30¥1.9bn
jpcrp040300-q1r_E04950-000Clinical Testing Businessreportable segmentsegment profit2021-04-01 → 2021-06-30¥304m
jpcrp040300-q1r_E04950-000Dispensing Pharmacy Businessreportable segmentrevenue2021-04-01 → 2021-06-30¥2.6bn
jpcrp040300-q1r_E04950-000Dispensing Pharmacy Businessreportable segmentrevenue external2021-04-01 → 2021-06-30¥2.6bn
jpcrp040300-q1r_E04950-000Dispensing Pharmacy Businessreportable segmentsegment profit2021-04-01 → 2021-06-30¥131m
jpcrp040300-q1r_E04950-000Medical Devices Sales And Maintenance Businessreportable segmentrevenue2021-04-01 → 2021-06-30¥710m
jpcrp040300-q1r_E04950-000Medical Devices Sales And Maintenance Businessreportable segmentrevenue external2021-04-01 → 2021-06-30¥170m
jpcrp040300-q1r_E04950-000Medical Devices Sales And Maintenance Businessreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥539m
jpcrp040300-q1r_E04950-000Medical Devices Sales And Maintenance Businessreportable segmentsegment profit2021-04-01 → 2021-06-30¥7m
—segment totalrevenue2021-04-01 → 2021-06-30¥5.2bn
—segment totalrevenue external2021-04-01 → 2021-06-30¥4.6bn
—segment totalrevenue intersegment2021-04-01 → 2021-06-30¥539m
—segment totalsegment profit2021-04-01 → 2021-06-30¥442m
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-06-30¥5.2bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-06-30¥4.6bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2021-06-30¥540m
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-06-30¥453m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 380
ItemContextValueUnit
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q1r_E04950-000MedicalDevicesSalesAndMaintenanceBusinessReportableSegmentsMember539457000JPY
Transactions with other segmentsPrior1YTDDuration_ReportableSegmentsMember539457000JPY
Transactions with other segmentsPrior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember351000JPY
Transactions with other segmentsPrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember539808000JPY
Net salesPrior1YTDDuration_jpcrp040300-q1r_E04950-000ClinicalTestingBusinessReportableSegmentsMember1879829000JPY
Net salesPrior1YTDDuration_jpcrp040300-q1r_E04950-000DispensingPharmacyBusinessReportableSegmentsMember2570114000JPY
Net salesPrior1YTDDuration_jpcrp040300-q1r_E04950-000MedicalDevicesSalesAndMaintenanceBusinessReportableSegmentsMember709804000JPY
Net salesPrior1YTDDuration_ReportableSegmentsMember5159749000JPY
Net salesPrior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember18872000JPY
Net salesPrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember5178621000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q1r_E04950-000ClinicalTestingBusinessReportableSegmentsMember303905000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q1r_E04950-000DispensingPharmacyBusinessReportableSegmentsMember131290000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q1r_E04950-000MedicalDevicesSalesAndMaintenanceBusinessReportableSegmentsMember7045000JPY
Operating incomePrior1YTDDuration_ReportableSegmentsMember442241000JPY
Operating incomePrior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember10577000JPY
Operating incomePrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember452818000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q1r_E04950-000ClinicalTestingBusinessReportableSegmentsMember2096762000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q1r_E04950-000DispensingPharmacyBusinessReportableSegmentsMember2548224000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q1r_E04950-000MedicalDevicesSalesAndMaintenanceBusinessReportableSegmentsMember232671000JPY
Revenues from external customersCurrentYTDDuration_ReportableSegmentsMember4877657000JPY
Revenues from external customersCurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember22392000JPY
Revenues from external customersCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember4900050000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q1r_E04950-000ClinicalTestingBusinessReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q1r_E04950-000DispensingPharmacyBusinessReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q1r_E04950-000MedicalDevicesSalesAndMaintenanceBusinessReportableSegmentsMember142990000JPY
Transactions with other segmentsCurrentYTDDuration_ReportableSegmentsMember142990000JPY
Transactions with other segmentsCurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember846000JPY
Transactions with other segmentsCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember143836000JPY
Net salesCurrentYTDDuration_jpcrp040300-q1r_E04950-000ClinicalTestingBusinessReportableSegmentsMember2096762000JPY
Net salesCurrentYTDDuration_jpcrp040300-q1r_E04950-000DispensingPharmacyBusinessReportableSegmentsMember2548224000JPY
Net salesCurrentYTDDuration_jpcrp040300-q1r_E04950-000MedicalDevicesSalesAndMaintenanceBusinessReportableSegmentsMember375661000JPY
Net salesCurrentYTDDuration_ReportableSegmentsMember5020648000JPY
Net salesCurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember23238000JPY
Net salesCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember5043886000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q1r_E04950-000ClinicalTestingBusinessReportableSegmentsMember199981000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q1r_E04950-000DispensingPharmacyBusinessReportableSegmentsMember77845000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q1r_E04950-000MedicalDevicesSalesAndMaintenanceBusinessReportableSegmentsMember-2699000JPY
Operating incomeCurrentYTDDuration_ReportableSegmentsMember275127000JPY
Operating incomeCurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember15288000JPY
Operating incomeCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember290416000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)四半期報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条の４の７第１項
Place of filing cover pageFilingDateInstant
Original text (Japanese)北海道財務局長
Filing date cover pageFilingDateInstant2022-08-10
Quarterly accounting period cover pageFilingDateInstant
Original text (Japanese)第59期第１四半期（自　2022年４月１日　至　2022年６月30日）
Company name cover pageFilingDateInstant
Original text (Japanese)札幌臨床検査センター株式会社
Company name in english cover pageFilingDateInstantSAPPORO CLINICAL LABORATORY INC.
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長　　伊達　忠應
Address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)札幌市中央区北三条西十八丁目２番地２
Telephone number address of registered headquarter cover pageFilingDateInstant０１１（６１３）３２１０

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-06-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-06-30pass